Please assess the completion status of the following clinical trial:

Trial Title: Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of RA (2010 American College of Rheumatology \[ACR\]/European League Against Rheumatism \[EULAR\] criteria for RA), and are ACR functional class I-III.~* Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints \[SJC66\]) and ≥6 tender joints (from a tender joint count based on 68 joints \[TJC68\]) at screening and Day 1~* Ongoing treatment with a stable prescription of 1 or 2 csDMARDs~* Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for the treatment of RA to which they have had an inadequate response or intolerance~Key Exclusion Criteria:~* Previous treatment with any janus kinase (JAK) inhibitor~NOTE: Other protocol Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
- Filgotinib 100 mg (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).